What is Essure?        Company History        Leadership

	Founded in 1992 and headquarterd in Northern California, Conceptus® (NASDAQ: CPTS) is engaged in the design, development, promotion and distribution of innovative medical products for use in the field of women's health. As pioneers in women’s healthcare, Conceptus is committed to providing minimally invasive solutions for women. Currently, the company is dedicated to offering women and physicians a better solution in birth control when their families are complete. The Essure Procedure The Essure procedure is the first and only proven minimally invasive form of permanent birth control. It can be performed in the comfort of a physician’s office in about 10 minutes without hormones, cutting, burning or the risks associated with general anesthesia or tubal ligation. Small, flexible micro-inserts are placed in the fallopian tubes through the cervix without incisions. Over the next several weeks, Essure works with a woman’s body to create a natural barrier around the micro-inserts to prevent sperm from reaching the eggs. Three months after the Essure procedure, a doctor performs an Essure Confirmation Test to confirm that the fallopian tubes are fully blocked and that the patient can rely on Essure for permanent birth control with full confidence. Market and Clinical Information In 2002, the U.S. Food and Drug Administration (FDA) granted approval to market the Essure® device in the United States, a market where over 700,000 tubal ligations (the leading form of birth control) and 400,000 vasectomies are performed annually. Additionally, there are 7.5 million women whose families are completed and remain on temporary methods of birth control. Many of these women do not want the risks of surgery and are unaware of the Essure procedure. Clinical data proves that the Essure procedure: is 99.8% effective with zero pregnancies based on 4 years of follow-up Allows for a rapid recovery Has a high patient satisfaction rating - Almost all women rated their satisfaction with the Essure procedure as “good” to “excellent” after the first week The Essure procedure is available in the United States, Europe, Australia, New Zealand, Canada, Mexico, Central and South America and the Middle East. Essure has gained market acceptance. The procedure has been featured in reputable sources, such as Time Magazine, MSNBC.com and The Doctors show, and has become the standard of care for many healthcare organizations and professionals. Hundreds of thousands of women have benefitted from the Essure procedure worldwide and the positive impact to the healthcare system is limitless. Awards and Recognition Conceptus continues to strive for excellence and is regularly recognized as a leader in the medical device industry. Below are some of Conceptus’ recent achievements. 2008 Conceptus among Silicon Valley/San Jose Business Journal’s Top 25 Medical Device Companies Conceptus ranked #12 on Deloitte & Touche’s Technology Fast 50, Silicon Valley list Conceptus ranked #239 on Deloitte & Touche’s Technology Fast 500, North America list 2006 Conceptus ranked #10 on Deloitte & Touche’s Technology Fast 50, Silicon Valley list Conceptus ranked #49 on Deloitte & Touche’s Technology Fast 500, North America list 2005 Conceptus awarded Frost & Sullivan Gynecology Surgical Devices’ Enabling Technology of the Year Conceptus among Deloitte & Touche’s Technology Fast 50, Silicon Valley list Conceptus ranked #4 on Deloitte & Touche’s Technology Fast 500, North America list 2003 Conceptus awarded WSGR Phoenix Hall of Fame Award for Most Promising New Product Trademarks and Patents Conceptus and Essure are registered trademarks and Your Family Is Complete Your Choice Is Clear is a service mark of Conceptus, Inc. The Essure system is covered under the following patents: U.S. Patent numbers 7,237,552; 6,871,650; 6,763,833; 6,709,667; 6,705,323; 6,684,884; 6,679,266; 6,634,361; 6,526,979; 6,176,240; 6,145,505; 5,746,769; 5,601,600 and other patents pending. Australian patent numbers 781,748; 781,739; 739,429; 715,261; 711,768; 707,705; 707,047 and other patents pending. European patent numbers 1366729; 1212019; 1018991; 0957845 and 0957844. Other international patents granted and pending from corresponding U.S. Patents.		Code of Business Conduct and Ethics Whistleblower Policy Compensation Committee Charter Nominating and Corporate Governance Committee Charter Disclosure Policy Statement Corporate Governance Guidelines Corporate Risk Policy Audit Committee Charter

Site Index | Contact Us | Privacy | Product Sites